Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This finding suggested that inhibition of CDK2 and pRb expression via upregulated p21 was involved in the downregulation of Pim-2-induced G<sub>0</sub>/G<sub>1</sub> cell cycle arrest in lung cancer and hematopoietic malignancy cells.
|
29541172 |
2018 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Next-generation CDK2/9 inhibition elicits marked antineoplastic effects in lung cancer via anaphase catastrophe and reduced PEA15 phosphorylation.
|
28376145 |
2017 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously reported that CDK2 antagonism causes lung cancer cells to undergo anaphase catastrophe and apoptosis through inhibition of phosphorylation of the centrosomal protein CP110.
|
26304236 |
2015 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These effects may result from the ability of miR-5100 to promote G1/S transition and downregulate cyclin D1 and cyclin-dependent kinases 2 (CDK2) expressions in lung cancer stable cells.
|
25754817 |
2015 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We previously discovered that CDK2 inhibition causes lung cancer cells with more than two centrosomes to undergo multipolar cell division leading to apoptosis, defined as anaphase catastrophe.
|
25808870 |
2015 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Selective up-regulation of CDK2 is critical for TLR9 signaling stimulated proliferation of human lung cancer cell.
|
19854217 |
2010 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notable findings in lung carcinoma include: (i) cyclin A/cdk2 plays a key role in cell proliferation, while protein amount of cyclin E does not necessarily reflect cellular proliferative activity, depending on the tumor type; (ii) CKI function not only as suppressors, but also as activators of cdk, depending on expression levels; and (iii) aberrant expression of cyclin/cdk can lead to apoptosis in vivo in humans.
|
15743317 |
2005 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The known cellular functions of the tumor suppressor genes most commonly affected in lung cancer are reviewed herein, including the retinoblastoma (Rb) gene on chromosome 13q14, the p53 gene on 17p13, and the cyclin-dependent kinase inhibitor (CDKN2) gene on 9p21.
|
9891228 |
1999 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Coincidental alterations of p16INK4A/CDKN2 and other genes in human lung cancer cell lines.
|
9673367 |
1998 |
Carcinoma of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One half of all cancer cell lines and one fourth of lung cancer cell lines examined to date contain homozygous deletions (i.e., both alleles lost) of CDKN2.
|
7563154 |
1995 |
Carcinoma of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both copies of the candidate tumor suppressor gene on chromosome 9, CDKN2, are deleted in approximately one-fourth of lung cancer cell lines examined and the protein product of CDKN2, p16 is undetectable in one-third of the lung cancer cell lines studied.
|
7551956 |
1995 |
Carcinoma of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In summary, inactivation of CDKN2 is implicated in the development of about 20% of NSCLC, but the possibility of another tumor suppressor gene on chromosome segment 9p21 important in lung cancer cannot be eliminated.
|
8589032 |
1995 |
Carcinoma of lung
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2'deoxycytidine.
|
7566983 |
1995 |